Company: ARWR
Filing Date: 2025-02-10
Form Type: 10-Q
Source: 0001628280-25-004634
Chunk: 15

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-02-10
Form: 10-Q
Item: Part I, Item 1
Chunk 15
---
15,209 19,694 Depreciation and amortization5,235 4,263 Accretion of note premiums/discounts(5,704)(835)Realized loss on investments— (80)Non-cash interest expense on liability related to the sale of future royalties5,415 5,367 Non-cash interest expense on credit facility16,231 — Changes in operating assets and liabilities:Accounts receivable(2,500)— Prepaid expenses and other assets(592)(1,748)Accounts payable3,069 (12,463)Accrued expenses(7,691)408 Deferred revenue— (866)Operating lease, net(1,128)3,796 Other1,402 — Net cash used in operating activities(146,272)(117,840)CASH FLOWS FROM INVESTING ACTIVITIES:Purchases of property and equipment(7,516)(68,656)Purchases of investments(33,749)— Proceeds from sales and maturities of investments118,175 133,495 Net cash provided by investing activities76,910 64,839 CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from the exercises of stock options634 267 Proceeds from the issuance of pre-funded warrants25,000 — Payments of debt issuance cost(5,000)— Net cash provided by financing activities20,634 267 Net decrease in cash, cash equivalents and restricted cash(48,728)(52,734)Effect of exchange rate on cash, cash equivalents and restricted cash(68)58 CASH, CASH EQUIVALENTS AND RESTRICTED CASH:BEGINNING OF PERIOD102,685 110,891 END OF PERIOD$53,889 $58,215 Supplementary disclosure of cash flows:Income taxes paid$(11)$(999)Supplemental disclosure of non-cash investing activities:Capital expenditures included in accrued expenses$2,574 $11,290 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

4

Arrowhead Pharmaceuticals, Inc.

Notes to Consolidated Financial Statements 

(unaudited)

NOTE 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

General and Recent DevelopmentsArrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the “Company”) are primarily engaged